Matinas BioPharma Holdings, Inc. — Form SCHEDULE 13D/A
Filed August 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Sanitam Partners LLC filed an amended Schedule 13D/A on August 13, 2026, regarding beneficial ownership in Matinas BioPharma Holdings, Inc. (market value ~$4.5M). The document text provided does not include the specific amended ownership percentages, share counts, or details of what changed from the prior filing—only administrative header information is visible.
Why this rating
Amendment to 13D is routine disclosure. Without concrete ownership %, share count, or strategic change details, cannot assess materiality. At ~$4.5M market cap, even a 5% stake shift would warrant closer look, but data absent here.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.